NR1H4 and metabolic dysfunction-associated steatohepatitis: TXR is a farnesoid X receptor agonist, whereas CVC is a chemokine receptor type 2/5 (CCR2 and CCR5) antagonist, and both target the pathways involved in NASH, i.e., steatotic, inflammatory, and/or fibrotic pathways.